Zymeworks Said to Near $929 Million Deal for Theravance - Bloomberg News

Analysts Offer Insights on Healthcare Companies: Nurix Therapeutics (NRIX), Taysha Gene Therapies (TSHA) and Zymeworks (ZYME)

PRESS Digest-canada - June 30

Analysts Are Bullish on Top Healthcare Stocks: BioCryst (BCRX), Zymeworks (ZYME)

Zymeworks, Inc. : Wells Fargo Raises Target Price to $37 from $34

Zymeworks price target raised to $37 from $35 at Citi

Zymeworks Down 6.1%

Zymeworks Posts Investor Presentation on Planned Theravance Biopharma Acquisition for Yupelri Cash Flows

Deals of the Day-mergers and Acquisitions

Why This Biotech Stock is Falling After a $929 Million Buyout Lifeline

Theravance Biopharma: Co to Pay $32.5 Mln Termination Fee to Zymeworks, if Deal Terminated Under Certain Circumstances

Theravance Biopharma to be acquired by Zymeworks for $17.00 per share in cash

Theravance Biopharma Shares Fall 3.3% Premarket; Co to be Acquired by Zymeworks for $17 Per Share in Cash Plus a Contingent Value Right

Zymeworks to Acquire Theravance Biopharma for USD 17 Per Share in USD 929 Million Deal

Theravance Biopharma - Strategic Review Committee and Board Unanimously Approve and Recommend Deal

Theravance Biopharma - Deal Represents Equity Value of About $929 Mln

Theravance Biopharma - to be Bought by Zymeworks for $17 Per Share in Cash Plus CVR

Theravance Biopharma - Shareholders to Receive CVR for 80% of Net Proceeds from Ampreloxetine Monetization

Zymeworks - Deal Financed by $350 Mln Non-recourse Note, $360 Mln Net Cash, $219 Mln Zymeworks Cash

Zymeworks - Deal Expected to be Accretive to Earnings and Cash Flow